News Room

Two drug companies have now reported highly successful results from phase III trials of COVID-19 vaccines. On November 18 Pfizer and partner BioNTech said their vaccine was 95 percent effective at preventing the disease, based on full trial results. Two days earlier Moderna reported its vaccine was 94.5 percent effective, based on interim data.

When Timothy Nuvangyaoma, chairman of the Hopi Tribe, heard there were two coronavirus vaccines that both showed promising data of more than 90 percent efficacy, he felt initial relief that soon transitioned to cautious skepticism.

Hospitals across the country are ramping up their efforts to figure out how to store, track and administer coronavirus vaccine doses following the recent news that an effective vaccine could be on its way within weeks or months. Hospitals will play a key role once a vaccine receives an emergency use authorization from the FDA, which could happen as soon as next month. They will move quickly to vaccinate their front-line healthcare workers and then their patients and surrounding communities.

Operation Warp Speed, a Trump administration initiative to manufacture COVID-19 vaccines as fast as possible, should be lauded as a successful endeavour in what has otherwise been a poor effort to deal with the coronavirus, experts say. "No doubt, Operation Warp Speed is a huge success," said Tinglong Dai, associate professor of Operations Management and Business Analytics at Johns Hopkins University Carey Business School in Baltimore.

As coronavirus ravages the U.S. population, the disease may be taking uninfected people with it. More people died from March through May this year than died last year, even after stripping out the numbers of people who have succumbed to COVID-19, according to a new study out of the University of Illinois at Urbana-Champaign.